The efficacy and safety of a fixed-dose combination of apocynin and paeonol, APPA, in symptomatic knee osteoarthritis (OA): A double-blind, randomized, placebo-controlled, clinical trial
Primary result · WOMAC painResult — go to the resultMean difference −0.89 95% CI −5.62 to 3.84Authors' conclusion
Treatment with APPA 800 mg twice daily for 28 days in subjects with symptomatic knee OA was not associated with significant symptom improvement compared to placebo. The treatment was well-tolerated and safe.
Study context
- Population
- People with symptomatic radiographic knee OA (KL grades 2–3) and pain ≥40/100 on WOMAC pain subscale148 completed
- Participants
- 152 people
- Comparison
- APPA 800 mg orally twice daily vs placebo for 28 days
- Primary endpoint
- WOMAC pain
- Follow-up
- 28 days
Methodological detailsmulticentre, double-blind, placebo-controlled, phase 2a, 1:1
- Multicentre
- Double-blind
- Placebo-controlled
- Phase 2a
- 1:1
Primary result
As reported in the abstract
Mean difference
−0.89
95% CI −5.62 to 3.84
P = 0.71
APPA 800 mg orally twice dailyvs placebo for 28 days
mean difference −0.89 (95% CI −5.62 to 3.84); P = 0.71
Further findings
WOMAC function and WOMAC total
- No statistically significant difference between groups
Predefined subgroup: nociplastic/neuropathic pain features
- Statistically significant effect of APPA compared to placebo
- Study not powered for such analysis
Original publication
The efficacy and safety of a fixed-dose combination of apocynin and paeonol, APPA, in symptomatic knee OA: A double-blind, randomized, placebo-controlled, clinical trial. Osteoarthritis Cartilage. Published 30 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →